RS56937B1 - Monoklonska anti-gt468 antitela za lečenje kancera - Google Patents

Monoklonska anti-gt468 antitela za lečenje kancera

Info

Publication number
RS56937B1
RS56937B1 RS20180160A RSP20180160A RS56937B1 RS 56937 B1 RS56937 B1 RS 56937B1 RS 20180160 A RS20180160 A RS 20180160A RS P20180160 A RSP20180160 A RS P20180160A RS 56937 B1 RS56937 B1 RS 56937B1
Authority
RS
Serbia
Prior art keywords
antibody
cells
antibodies
cancer
cell
Prior art date
Application number
RS20180160A
Other languages
English (en)
Serbian (sr)
Inventor
Ugur Sahin
Özlem Türeci
Michael Koslowski
Rita Mitnacht-Kraus
Original Assignee
Ganymed Pharmaceuticals Gmbh
Univ Mainz Johannes Gutenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Gmbh, Univ Mainz Johannes Gutenberg filed Critical Ganymed Pharmaceuticals Gmbh
Publication of RS56937B1 publication Critical patent/RS56937B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20180160A 2008-09-16 2009-09-16 Monoklonska anti-gt468 antitela za lečenje kancera RS56937B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9745308P 2008-09-16 2008-09-16
EP08016277A EP2166021A1 (en) 2008-09-16 2008-09-16 Monoclonal antibodies for treatment of cancer
EP09778564.6A EP2342234B1 (en) 2008-09-16 2009-09-16 Monoclonal anti-gt468 antibodies for treatment of cancer
PCT/EP2009/006704 WO2010031551A2 (en) 2008-09-16 2009-09-16 Monoclonal antibodies for treatment of cancer

Publications (1)

Publication Number Publication Date
RS56937B1 true RS56937B1 (sr) 2018-05-31

Family

ID=40589589

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180160A RS56937B1 (sr) 2008-09-16 2009-09-16 Monoklonska anti-gt468 antitela za lečenje kancera

Country Status (27)

Country Link
US (1) US8946388B2 (cg-RX-API-DMAC7.html)
EP (3) EP2166021A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012502938A (cg-RX-API-DMAC7.html)
KR (1) KR101818741B1 (cg-RX-API-DMAC7.html)
CN (3) CN105753988A (cg-RX-API-DMAC7.html)
AU (1) AU2009294896B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0918178B8 (cg-RX-API-DMAC7.html)
CA (1) CA2732594C (cg-RX-API-DMAC7.html)
CY (1) CY1119956T1 (cg-RX-API-DMAC7.html)
DK (1) DK2342234T3 (cg-RX-API-DMAC7.html)
ES (1) ES2659718T3 (cg-RX-API-DMAC7.html)
HK (1) HK1253579A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20180262T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036477T2 (cg-RX-API-DMAC7.html)
IL (2) IL211010A (cg-RX-API-DMAC7.html)
LT (1) LT2342234T (cg-RX-API-DMAC7.html)
MX (2) MX357010B (cg-RX-API-DMAC7.html)
NO (1) NO2342234T3 (cg-RX-API-DMAC7.html)
NZ (2) NZ596490A (cg-RX-API-DMAC7.html)
PL (1) PL2342234T3 (cg-RX-API-DMAC7.html)
PT (1) PT2342234T (cg-RX-API-DMAC7.html)
RS (1) RS56937B1 (cg-RX-API-DMAC7.html)
SI (1) SI2342234T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800079T1 (cg-RX-API-DMAC7.html)
TR (1) TR201802090T4 (cg-RX-API-DMAC7.html)
WO (1) WO2010031551A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100835B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CN103459424B (zh) * 2011-01-19 2017-11-10 坎塔吉亚有限责任公司 抗il1rap抗体及其治疗人类的用途
US20130236890A1 (en) * 2012-03-08 2013-09-12 HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells
KR101471253B1 (ko) * 2012-10-29 2014-12-10 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
EP3858341A1 (en) 2012-11-15 2021-08-04 Endocyte, Inc. Psma ligand-containing conjugates for the treatment of prostate cancer
KR101947053B1 (ko) 2013-10-18 2019-02-12 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
JP2017521998A (ja) * 2014-05-12 2017-08-10 ヌマブ アクチェンゲゼルシャフト 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016161410A2 (en) * 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
CA2992091A1 (en) * 2015-07-14 2017-01-19 Medimmune, Llc Compositions and methods for treating cancer
EP3344278A4 (en) * 2015-09-04 2019-01-23 The California Institute for Biomedical Research INSULIN-IMMUNOGLOBULIN FUSION PROTEINS
WO2017093447A1 (en) * 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
BR112019008010A2 (pt) * 2016-10-20 2019-07-09 I Mab anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CN106632661A (zh) * 2017-01-10 2017-05-10 天津东亚生物技术有限公司 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用
CN108124445B (zh) * 2017-03-15 2021-05-04 苏州银河生物医药有限公司 Ctla4抗体、其药物组合物及其用途
CN107556369A (zh) * 2017-08-23 2018-01-09 天津国际生物医药联合研究院 一种抗原肽和用于检测肿瘤细胞的抗体制备方法及其应用
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
KR102266418B1 (ko) * 2019-07-30 2021-06-16 한국생명공학연구원 영여자 추출물을 유효성분으로 함유하는 전립선 질환의 예방 및 치료용 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5744585A (en) 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7129084B2 (en) 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003075014A2 (en) 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
PT1558648E (pt) 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
WO2004065629A1 (en) 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CN1663603A (zh) 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
WO2010094499A1 (en) 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer

Also Published As

Publication number Publication date
EP3312198A1 (en) 2018-04-25
US20110223182A1 (en) 2011-09-15
NO2342234T3 (cg-RX-API-DMAC7.html) 2018-04-14
IL242204B (en) 2020-09-30
AU2009294896B2 (en) 2015-04-30
CA2732594C (en) 2019-05-28
DK2342234T3 (en) 2018-02-26
CN105753988A (zh) 2016-07-13
LT2342234T (lt) 2018-03-12
AU2009294896A1 (en) 2010-03-25
SMT201800079T1 (it) 2018-03-08
PL2342234T3 (pl) 2018-07-31
NZ596490A (en) 2013-05-31
CN104628858B (zh) 2018-11-16
CN104628858A (zh) 2015-05-20
ZA201100835B (en) 2014-04-30
JP2012502938A (ja) 2012-02-02
HK1253579A1 (en) 2019-06-21
KR20110055699A (ko) 2011-05-25
HUE036477T2 (hu) 2018-07-30
CN102164963B (zh) 2015-07-29
MX2011002856A (es) 2011-06-28
CN102164963A (zh) 2011-08-24
KR101818741B1 (ko) 2018-01-15
WO2010031551A3 (en) 2010-09-16
EP2342234B1 (en) 2017-11-15
SI2342234T1 (en) 2018-04-30
EP2342234A2 (en) 2011-07-13
IL211010A0 (en) 2011-04-28
BRPI0918178B1 (pt) 2021-04-06
CY1119956T1 (el) 2018-12-12
TR201802090T4 (tr) 2018-03-21
US8946388B2 (en) 2015-02-03
BRPI0918178A8 (pt) 2020-05-19
EP2166021A1 (en) 2010-03-24
BRPI0918178A2 (pt) 2015-12-01
NZ591004A (en) 2012-03-30
IL242204A0 (en) 2015-11-30
BRPI0918178B8 (pt) 2021-05-25
IL211010A (en) 2015-11-30
ES2659718T3 (es) 2018-03-19
MX357010B (es) 2018-06-22
PT2342234T (pt) 2018-02-21
HRP20180262T1 (hr) 2018-03-23
CA2732594A1 (en) 2010-03-25
WO2010031551A2 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
CN102164963B (zh) 用于治疗癌症的单克隆抗体
CN101754979B (zh) 用于治疗癌症的单克隆抗体
US10596256B2 (en) Monoclonal anti-GT 468 antibodies for treatment of cancer
AU2015205868B2 (en) Monoclonal antibodies for treatment of cancer
HK40000187A (en) Monoclonal antibodies for treatment of cancer
HK1157362A (en) Monoclonal anti-gt468 antibodies for treatment of cancer
HK1157362B (en) Monoclonal anti-gt468 antibodies for treatment of cancer
HK1174647A (en) Monoclonal antibodies for treatment of cancer